BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/12/2014 8:41:00 PM | Browse: 678 | Download: 479
Publication Name World Journal of Gastroenterology
Manuscript ID 3571
Country/Territory China
2013-05-07 08:46
Peer-Review Started
2013-05-07 10:57
To Make the First Decision
2013-07-05 18:31
Return for Revision
2013-07-17 10:34
2013-08-13 00:19
Second Decision
2013-09-13 14:56
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-09-13 22:43
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-10-17 10:34
Publish the Manuscript Online
2013-11-13 08:37
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Autobiography
Article Title Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis
Manuscript Source Invited Manuscript
All Author List Chang-Zheng Li, Liu-Fang Cheng, Qing-Shan Li, Zhi-Qiang Wang and Jun-Hong Yan
Funding Agency and Grant Number
Corresponding author Chang-Zheng Li, MD, Department of Gastroenterology and Hepatology, Institute of Hepatobiliary and Gastrointestinal Diseases, Chinese Second Artillery General Hospital, No. 16, Xinjiekouwai Street, Xicheng District, Beijing 100088, China. licz007@aliyun.com
Keywords Nucleoside analog; Esophageal variceal bleeding; Hepatitis B virus; Cirrhosis; Resistance; Entecavir; Lamivudine; Adefovir
Core Tip Antiviral therapy with nucleoside analogs improves clinical outcome in hepatitis B virus (HBV)-related decompensated cirrhosis. However, the emergence of resistance results in liver injury. The consequences may be worse in patients with esophageal varices (EV), in which bleeding and death often occur. This study evaluated the efficacy of antiviral treatment over 5 years in patients with HBV-related cirrhosis and EV and found that antiviral therapy decreased the risk of bleeding. However, agents with a high rate of virological breakthrough were ineffective in preventing bleeding. These findings provide evidence-based suggestions for the treatment of this special group of patients.
Publish Date 2013-11-13 08:37
Citation Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol 2013; 19(40): 6849-6856
Url http://www.wjgnet.com/1007-9327/full/v19/i40/6849.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i40.6849
Full Article (PDF) WJG-19-6849.pdf
Manuscript File 3571-Review.doc
Answering Reviewers 3571-Answering reviewers.pdf
Copyright License Agreement 3571-Copyright assignment.doc
Non-Native Speakers of English Editing Certificate 3571-Language certificate.doc
Peer-review Report 3571-Peer reviewer(s).pdf
Scientific Editor Work List 3571-Scientific editor work list.doc